Lilly Drug Leads to 24 Percent Weight Loss in Trial

Published on June 27, 2023

A breakthrough obesity drug called ‘triple G’ from Eli Lilly has shown remarkable results in a mid-stage trial. The drug, retatrutide, led to an impressive 24.2% weight loss after 48 weeks, outperforming other weight loss medications. This once-weekly injected drug presents a promising solution for those struggling with obesity. Just like how high-quality fertilizer helps plants grow stronger and healthier, retatrutide acts as a catalyst in the body, aiding in significant weight reduction. The results from this trial are incredibly exciting and suggest that retatrutide could be a game-changer in the fight against obesity. It’s essential to understand that weight loss can have a profound impact on overall health, from reducing the risk of chronic diseases to improving mental well-being. With ongoing research and development in the field, there is hope for many more breakthroughs like this in the future. Dive deeper into the research to explore the potential of this groundbreaking obesity drug!

Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate “triple G” showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs. The once-weekly injected drug, retatrutide, is part of a…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>